THRM 8-K
Gentherm Inc (THRM)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 2, 2022, Gentherm Incorporated (the “Company”) publicly announced its financial results for the second quarter of 2022. A copy of the Company’s news release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
On August 2, 2022 at 8:00 a.m. Eastern Time, the Company will host a conference call to discuss the second quarter of 2022 financial results. A copy of the supplemental materials that will be used during the conference call is attached hereto as Exhibit 99.2 and is incorporated herein by reference.
The information in Items 2.02 and 7.01 herein and the attached exhibits 99.1 and 99.2 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly stated by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit 99.1 |
|
Company news release dated August 2, 2022 concerning financial results |
Exhibit 99.2 |
|
|
Exhibit 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
GENTHERM INCORPORATED |
||
|
|
|
|
|
By: |
|
/s/ Wayne Kauffman |
|
|
|
Wayne Kauffman |
|
|
|
Senior Vice President, General Counsel and Secretary |
Date: August 2, 2022 |
|
|
|
|
|
Exhibit 99.1
Gentherm Reports 2022 Second Quarter Results
and Announces New ClimateSenseTM Award
Automotive Revenue Growth Outperformed Light Vehicle Production Despite Significant Supply Chain Headwinds
Receives Second Production Vehicle Award for the ClimateSense™ Technology
Secured $600 Million in New Automotive Awards (Pro Forma)
Strategic Acquisition Expands Gentherm Medical’s Access to Large and Rapidly Growing Markets
Updates 2022 Guidance
NORTHVILLE, Michigan, August 2, 2022 /Global Newswire/ -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry, today announced its financial results for the second quarter ending June 30, 2022.
Second Quarter Highlights
Phil Eyler, the Company's President and CEO, said “Our results for the quarter reflect the extremely challenging operating environment our industry is facing. I am proud of the Gentherm team for the ongoing progress in stringent cost management and negotiating appropriate cost recoveries from customers in the face of unprecedented supply chain disruptions, semiconductor shortages, and inflationary pressure while maximizing performance towards customer needs. In Automotive, we outperformed actual light vehicle production in our key markets by approximately 600 basis points as customer demand for our products continues to grow. In addition, we secured $600 million of new awards from auto makers around the world as the largest global supplier of thermal and pneumatic comfort following the recent closing of the Alfmeier acquisition.
Eyler continued, “I am also pleased to announce that we recently received our second ClimateSenseTM award from a global OEM for our software-driven microclimate platform using an algorithm based on thermophysiology. ClimateSenseTM is a critical part of our long-term strategy and continues to gain interest from global OEMs for significantly reducing power consumption and increasing range all while providing best in class passenger comfort.
|
|
“While the difficult market conditions are expected to continue in the near-term, we remain focused on executing against our long-term strategic growth roadmap and returning to high-teens EBITDA margin rate. Gentherm is a pioneer in the application of thermophysiology and now, combined with Alfmeier’s pneumatic massage physiotherapy, the Company is well positioned to continue to lead the way in health, wellness, comfort and energy efficiency solutions to drive long-term shareholder value.”
Acquisition of Jiangmen Dacheng Medical Equipment Co. Ltd.
Dacheng, a privately held company headquartered in Jiangmen, Guangdong Province, China, is a developer and manufacturer of patient temperature management solutions for numerous Chinese and international customers. The acquisition provides Gentherm Medical with a leading commercial and manufacturing presence and well-established reputation in China’s emerging high-growth market for patient warming devices. The acquisition also allows Gentherm Medical to become a private label supplier to existing Dacheng customers, enabled by the expanded product development and high-tech manufacturing capability of the company. Dacheng’s products have regulatory approvals in many countries including China, United States, and Brazil.
“Dacheng is an existing supplier for Gentherm Medical with whom we have developed a strong relationship over many years. This acquisition provides enhanced access to high growth markets including private label opportunities through Dacheng’s innovative patient temperature management devices,” said Steve Fletcher, Senior Vice President and General Manager of Gentherm Medical. “This transaction significantly expands our manufacturing capabilities through added capacity and proprietary automated processes, giving us a manufacturing footprint in both the United States and China. We are excited to welcome Dacheng to the Gentherm team.”
2022 Second Quarter Financial Review
Product revenues for the second quarter of 2022 decreased by $5.3 million, or 2.0%, as compared with the prior-year period. Excluding the impact of foreign currency translation, product revenues increased 3.1% year over year.
Automotive revenues decreased 2.3% year over year. Excluding the impact of foreign currency translation, organic Automotive revenues increased 2.9% year over year primarily due to growth in Steering Wheel Heaters, Battery Performance Solutions, Climate Controlled Seat and Other Automotive. According to IHS Markit’s mid-July 2022 report, actual light vehicle production decreased by 2.6% in the current year’s second quarter when compared with the second quarter of 2021 in the Company’s key markets of North America, Europe, China, Japan and Korea.
Gentherm Medical revenue increased 6.1% year over year. Excluding the impact of foreign currency translation, Medical revenue increased 8.6% year over year primarily as a result of higher Warm Air and UV Treo product sales
See the “Revenues by Product Category” table included below for additional detail.
|
|
Gross margin rate decreased to 22.8% in the current-year period, as compared with 29.8% in the prior-year period. The decrease from the prior-year period resulted from higher costs incurred to mitigate the impact of the supply chain disruptions primarily in the form of premium freight and spot buys, inflation associated with wages, material and freight costs, as well as the negative impact of foreign currency translation. These were partially offset by cost recoveries and negotiated lower annual price reductions from customers.
Net research and development expenses of $19.3 million in the 2022 second quarter increased $1.1 million, or 6.0% over the prior-year period, primarily due to increased project-related spending as the Company continues to invest in ClimateSenseTM and Battery Performance Solution.
Selling, general and administrative expenses of $31.9 million in the 2022 second quarter increased $4.7 million, or 17.3%, versus the prior-year period. The year-over-year increase was primarily driven by acquisition related costs.
Acquisition expenses of $3.8 million in the current-year period were $3.0 million higher than the prior-year period as a result of expenses associated with the Alfmeier acquisition. Restructuring expenses of $0.4 million in the current-year period were $1.7 million lower than the prior-year period.
As described more fully in the “Reconciliation of Net Income to Adjusted EBITDA” table included below, the Company recorded Adjusted EBITDA of $21.4 million in the 2022 second quarter compared with $43.7 million in the prior-year period, a decrease of $22.3 million or 51.0%.
Income tax expense in the 2022 second quarter was $3.9 million, as compared with $5.7 million in the prior-year period. The effective tax rate was 35.7% in the 2022 second quarter. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, and the unfavorable impact of the global intangible low-tax income.
GAAP diluted earnings per share for the second quarter of 2022 was $0.21 compared with $0.74 for the prior-year period. Adjusted diluted earnings per share, excluding acquisition expenses, unrealized currency (gain) losses, non-cash purchase accounting impact and restructuring expenses (see table herein), was $0.25. Adjusted diluted earnings per share in the prior-year period was $0.85.
|
|
Guidance
The Company updates its full-year 2022 guidance that was initially provided on its year-end 2021 earnings release on February 17, 2022, based on year-to-date performance and to include the completed acquisition of Alfmeier as of August 1, 2022 and the completed acquisition of Dacheng Medical as of July 13, 2022:
Conference Call
As previously announced, Gentherm will conduct a conference call today at 8:00 am Eastern Time to review these results. The dial-in number for the call is 1-877-407-4018 (callers in the U.S.) or +1-201-689-8471 (callers outside this U.S.). The passcode for the live call is 13731484.
A live webcast and one-year archived replay of the call can be accessed on the Events page of the Investor section of Gentherm's website at www.gentherm.com.
A telephonic replay will be available at approximately two hours after the call until 11:59 pm Eastern Time on August 16, 2022. The replay can be accessed by dialing 1-844-512-2921 (callers in the U.S.), or +1-412-317-6671 (callers outside the U.S.). The passcode for the replay is 13731484.
Investor Relations Contact
Yijing Brentano
[email protected]
(248) 308-1702
Media Contact
Melissa Fischer
(248) 289-9702
|
|
About Gentherm
Gentherm (NASDAQ:THRM) is the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, cable systems, lumbar and massage comfort solutions, valve system technologies, and other electronic devices. Medical products include patient temperature management systems. The Company is also developing a number of new technologies and products that will help enable improvements to existing products and to create new product applications for existing and new markets. Gentherm has more than 13,000 employees in facilities in the United States, Germany, China, Czech Republic, Hungary, Japan, Malta, Mexico, North Macedonia, South Korea, United Kingdom, Ukraine, and Vietnam. For more information, go to www.gentherm.com.
Forward-Looking Statements
Except for historical information contained herein, statements in this release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this release are made as of the date hereof or as of the date specified herein and are based on management's reasonable expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause actual results or performance to differ materially from that described in or indicated by the forward-looking statements, including that:
|
|
|
|
The foregoing risks should be read in conjunction with the Company's filings with the Securities and Exchange Commission (the “SEC”), including “Risk Factors”, in its most recent Annual Report on Form 10-K and subsequent SEC filings, for a discussion of these and other risks and uncertainties. In addition, the business outlook discussed in this release does not include the impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof, each of which may present material risks to the Company’s future business and financial results.
Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
|
|
GENTHERM INCORPORATED
CONSOLIDATED CONDENSED STATEMENTS OF INCOME
(In thousands, except per share data)
(Unaudited)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Product revenues |
|
$ |
260,715 |
|
|
$ |
266,005 |
|
|
$ |
528,372 |
|
|
$ |
554,540 |
|
Cost of sales |
|
|
201,338 |
|
|
|
186,792 |
|
|
|
404,882 |
|
|
|
387,658 |
|
Gross margin |
|
|
59,377 |
|
|
|
79,213 |
|
|
|
123,490 |
|
|
|
166,882 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net research and development expenses |
|
|
19,325 |
|
|
|
18,227 |
|
|
|
39,759 |
|
|
|
35,830 |
|
Selling, general and administrative expenses |
|
|
31,943 |
|
|
|
27,223 |
|
|
|
61,251 |
|
|
|
55,749 |
|
Restructuring expenses |
|
|
374 |
|
|
|
2,091 |
|
|
|
555 |
|
|
|
2,882 |
|
Total operating expenses |
|
|
51,642 |
|
|
|
47,541 |
|
|
|
101,565 |
|
|
|
94,461 |
|
Operating income |
|
|
7,735 |
|
|
|
31,672 |
|
|
|
21,925 |
|
|
|
72,421 |
|
Interest expense, net |
|
|
(1,430 |
) |
|
|
(630 |
) |
|
|
(1,999 |
) |
|
|
(1,669 |
) |
Foreign currency gain (loss) |
|
|
4,552 |
|
|
|
(515 |
) |
|
|
6,769 |
|
|
|
258 |
|
Other income |
|
|
134 |
|
|
|
12 |
|
|
|
338 |
|
|
|
3 |
|
Earnings before income tax |
|
|
10,991 |
|
|
|
30,539 |
|
|
|
27,033 |
|
|
|
71,013 |
|
Income tax expense |
|
|
3,919 |
|
|
|
5,748 |
|
|
|
8,214 |
|
|
|
13,313 |
|
Net income |
|
$ |
7,072 |
|
|
$ |
24,791 |
|
|
$ |
18,819 |
|
|
$ |
57,700 |
|
Basic earnings per share |
|
$ |
0.21 |
|
|
$ |
0.75 |
|
|
$ |
0.57 |
|
|
$ |
1.75 |
|
Diluted earnings per share |
|
$ |
0.21 |
|
|
$ |
0.74 |
|
|
$ |
0.56 |
|
|
$ |
1.72 |
|
Weighted average number of shares – basic |
|
|
33,119 |
|
|
|
33,100 |
|
|
|
33,077 |
|
|
|
33,025 |
|
Weighted average number of shares – diluted |
|
|
33,426 |
|
|
|
33,544 |
|
|
|
33,422 |
|
|
|
33,469 |
|
|
|
GENTHERM INCORPORATED
REVENUE BY PRODUCT CATEGORY AND RECONCILIATION OF FOREIGN CURRENCY TRANSLATION IMPACT
(In thousands)
(Unaudited)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||||||||
|
|
2022 |
|
|
2021 |
|
% Change |
|
|
2022 |
|
|
2021 |
|
% Change |
|
||||||
Climate Control Seat |
|
$ |
96,488 |
|
|
$ |
98,229 |
|
|
(1.8 |
)% |
|
$ |
199,222 |
|
|
$ |
207,402 |
|
|
(3.9 |
)% |
Seat Heaters |
|
|
65,903 |
|
|
|
69,864 |
|
|
(5.7 |
)% |
|
|
134,799 |
|
|
|
146,585 |
|
|
(8.0 |
)% |
Steering Wheel Heaters |
|
|
28,951 |
|
|
|
26,697 |
|
|
8.4 |
% |
|
|
57,687 |
|
|
|
55,561 |
|
|
3.8 |
% |
Automotive Cables |
|
|
19,280 |
|
|
|
22,940 |
|
|
(16.0 |
)% |
|
|
41,325 |
|
|
|
47,221 |
|
|
(12.5 |
)% |
Battery Performance Solutions |
|
|
17,451 |
|
|
|
17,577 |
|
|
(0.7 |
)% |
|
|
35,064 |
|
|
|
35,337 |
|
|
(0.8 |
)% |
Electronics |
|
|
10,278 |
|
|
|
14,652 |
|
|
(29.9 |
)% |
|
|
21,106 |
|
|
|
29,757 |
|
|
(29.1 |
)% |
Other Automotive |
|
|
10,801 |
|
|
|
5,146 |
|
|
109.9 |
% |
|
|
17,813 |
|
|
|
12,612 |
|
|
41.2 |
% |
Subtotal Automotive segment |
|
|
249,152 |
|
|
|
255,105 |
|
|
(2.3 |
)% |
|
|
507,016 |
|
|
|
534,475 |
|
|
(5.1 |
)% |
Medical segment |
|
|
11,563 |
|
|
|
10,900 |
|
|
6.1 |
% |
|
|
21,356 |
|
|
|
20,065 |
|
|
6.4 |
% |
Total Company |
|
$ |
260,715 |
|
|
$ |
266,005 |
|
|
(2.0 |
)% |
|
$ |
528,372 |
|
|
$ |
554,540 |
|
|
(4.7 |
)% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Foreign currency translation impact |
|
|
(13,569 |
) |
|
|
— |
|
|
|
|
|
(20,170 |
) |
|
|
— |
|
|
|
||
Total Company, excluding foreign |
|
$ |
274,284 |
|
|
$ |
266,005 |
|
|
3.1 |
% |
|
$ |
548,542 |
|
|
$ |
554,540 |
|
|
(1.1 |
)% |
|
|
GENTHERM INCORPORATED
RECONCILIATION OF NET INCOME TO ADJUSTED EBITDA
(In thousands)
(Unaudited)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Net income |
|
$ |
7,072 |
|
|
$ |
24,791 |
|
|
$ |
18,819 |
|
|
$ |
57,700 |
|
Add back: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Depreciation and amortization |
|
|
8,998 |
|
|
|
9,628 |
|
|
|
18,485 |
|
|
|
19,323 |
|
Income tax expense |
|
|
3,919 |
|
|
|
5,748 |
|
|
|
8,214 |
|
|
|
13,313 |
|
Interest expense |
|
|
1,430 |
|
|
|
630 |
|
|
|
1,999 |
|
|
|
1,669 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Restructuring expense |
|
|
374 |
|
|
|
2,091 |
|
|
|
555 |
|
|
|
2,882 |
|
Unrealized currency gain |
|
|
(4,024 |
) |
|
|
(11 |
) |
|
|
(6,340 |
) |
|
|
(306 |
) |
Acquisition expenses |
|
|
3,794 |
|
|
|
844 |
|
|
|
7,008 |
|
|
|
958 |
|
Other |
|
|
(128 |
) |
|
|
— |
|
|
|
(326 |
) |
|
|
— |
|
Adjusted EBITDA |
|
$ |
21,435 |
|
|
$ |
43,721 |
|
|
$ |
48,414 |
|
|
$ |
95,539 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Product revenues |
|
$ |
260,715 |
|
|
$ |
266,005 |
|
|
$ |
528,372 |
|
|
$ |
554,540 |
|
Adjusted EBITDA % |
|
|
8.2 |
% |
|
|
16.4 |
% |
|
|
9.2 |
% |
|
|
17.2 |
% |
Use of Non-GAAP Financial Measures
In addition to the results reported in accordance with GAAP throughout this release, the Company has provided here or elsewhere information regarding adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”), Adjusted EBITDA margin, adjusted earnings per share (“Adjusted earnings per share” or “Adjusted EPS”), free cash flow, Net Debt and Revenue excluding the impact of foreign currency translation, each a non-GAAP financial measure. The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, deferred financing cost amortization, and other gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company defines Adjusted EBITDA margin as Adjusted EBITDA divided by product revenues. The Company defines Adjusted EPS as earnings adjusted by gains and losses not reflective of the Company’s ongoing operations and related tax effects including transaction expenses, debt retirement expenses, impairment of assets held for sale, gain or loss on sale of business, restructuring expense, unrealized currency gain or loss and unrealized revaluation of derivatives. The Company defines Free Cash Flow as Net cash (used in) provided by operating activities less Purchases of property and equipment. The Company defines Net Debt as the principal amount of all Consolidated Funded Indebtedness (as defined in the Credit Agreement) less cash and cash equivalents. The Company defines Revenue excluding the impact of foreign currency translation as revenue, less the estimated effects of foreign currency exchange on revenue by translating actual revenue using the prior period foreign currency exchange rates.
The Company’s reconciliations are included in this release or can be found in the supplemental materials furnished as Exhibit 99.2 to the Company’s Form 8-K dated August 2, 2022.
|
|
In evaluating its business, the Company considers and uses Free Cash Flow and Net Debt as supplemental measures of its liquidity and the other non-GAAP financial measures as supplemental measures of its operating performance. Management provides such non-GAAP financial measures so that investors will have the same financial information that management uses with the belief that it will assist investors in properly assessing the Company's performance on a period-over-period basis by excluding matters not indicative of the Company’s ongoing operating or liquidity results. In evaluating our non-GAAP financial measures, you should be aware that in the future we may incur revenues, expenses, and cash and non-cash obligations that are the same as or similar to some of the adjustments in our presentation of non-GAAP financial measures. Our presentation of non-GAAP financial measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. There also can be no assurance that we will not modify the presentation of our non-GAAP financial measures in the future, and any such modification may be material. Other companies in our industry may define and calculate these non-GAAP financial measures differently than we do and those calculations may not be comparable to our metrics. These non-GAAP measures have limitations as analytical tools, and when assessing the Company's operating performance or liquidity, investors should not consider these non-GAAP measures in isolation, or as a substitute for net income, revenue or other consolidated income statement or cash flow statement data prepared in accordance with GAAP.
Non-GAAP measures referenced in this release and other public communications may include estimates of future Adjusted EBITDA, Adjusted EBITDA margin and Adjusted EPS. Such forward-looking non-GAAP measures may differ significantly from the corresponding GAAP measures, due to depreciation and amortization, tax expense, and/or interest expense, some or all of which management has not quantified for the future periods.
|
|
GENTHERM INCORPORATED
ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE
(In thousands, except per share data)
(Unaudited)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Net income |
|
$ |
7,072 |
|
|
$ |
24,791 |
|
|
$ |
18,819 |
|
|
$ |
57,700 |
|
Non-cash purchase accounting impact |
|
|
1,749 |
|
|
|
2,050 |
|
|
|
3,584 |
|
|
|
4,100 |
|
Restructuring expenses |
|
|
374 |
|
|
|
2,091 |
|
|
|
555 |
|
|
|
2,882 |
|
Unrealized currency gain |
|
|
(4,024 |
) |
|
|
(11 |
) |
|
|
(6,340 |
) |
|
|
(306 |
) |
Acquisition expenses |
|
|
3,794 |
|
|
|
844 |
|
|
|
7,008 |
|
|
|
958 |
|
Other |
|
|
(128 |
) |
|
|
— |
|
|
|
(326 |
) |
|
|
— |
|
Tax effect of above |
|
|
(462 |
) |
|
|
(1,311 |
) |
|
|
(1,198 |
) |
|
|
(1,991 |
) |
Adjusted net income |
|
$ |
8,375 |
|
|
$ |
28,454 |
|
|
$ |
22,102 |
|
|
$ |
63,343 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted average shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
|
33,119 |
|
|
|
33,100 |
|
|
|
33,077 |
|
|
|
33,025 |
|
Diluted |
|
|
33,426 |
|
|
|
33,544 |
|
|
|
33,422 |
|
|
|
33,469 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Earnings per share, as reported: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
0.21 |
|
|
$ |
0.75 |
|
|
$ |
0.57 |
|
|
$ |
1.75 |
|
Diluted |
|
$ |
0.21 |
|
|
$ |
0.74 |
|
|
$ |
0.56 |
|
|
$ |
1.72 |
|
Adjusted earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Basic |
|
$ |
0.25 |
|
|
$ |
0.86 |
|
|
$ |
0.67 |
|
|
$ |
1.92 |
|
Diluted |
|
$ |
0.25 |
|
|
$ |
0.85 |
|
|
$ |
0.66 |
|
|
$ |
1.89 |
|
|
|
GENTHERM INCORPORATED
CONSOLIDATED CONDENSED BALANCE SHEETS
(In thousands, except share data)
(Unaudited)
|
|
June 30, 2022 |
|
|
December 31, 2021 |
|
||
ASSETS |
|
|
|
|
|
|
||
Current Assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
157,258 |
|
|
$ |
190,606 |
|
Accounts receivable, net |
|
|
207,364 |
|
|
|
182,987 |
|
Inventory: |
|
|
|
|
|
|
||
Raw materials |
|
|
122,371 |
|
|
|
96,426 |
|
Work in process |
|
|
8,989 |
|
|
|
9,495 |
|
Finished goods |
|
|
56,424 |
|
|
|
53,556 |
|
Inventory, net |
|
|
187,784 |
|
|
|
159,477 |
|
Other current assets |
|
|
40,320 |
|
|
|
32,775 |
|
Total current assets |
|
|
592,726 |
|
|
|
565,845 |
|
Property and equipment, net |
|
|
149,907 |
|
|
|
155,270 |
|
Goodwill |
|
|
62,935 |
|
|
|
66,033 |
|
Other intangible assets, net |
|
|
31,968 |
|
|
|
37,554 |
|
Operating lease right-of-use assets |
|
|
25,924 |
|
|
|
24,387 |
|
Deferred income tax assets |
|
|
67,112 |
|
|
|
69,630 |
|
Other non-current assets |
|
|
16,474 |
|
|
|
16,624 |
|
Total assets |
|
$ |
947,046 |
|
|
$ |
935,343 |
|
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
|
|
|
||
Current Liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
147,136 |
|
|
$ |
122,727 |
|
Current lease liabilities |
|
|
5,376 |
|
|
|
5,669 |
|
Current maturities of long-term debt |
|
|
2,500 |
|
|
|
2,500 |
|
Other current liabilities |
|
|
84,206 |
|
|
|
82,193 |
|
Total current liabilities |
|
|
239,218 |
|
|
|
213,089 |
|
Long-term debt, less current maturities |
|
|
35,000 |
|
|
|
36,250 |
|
Non-current lease liabilities |
|
|
18,721 |
|
|
|
19,789 |
|
Pension benefit obligation |
|
|
6,116 |
|
|
|
6,832 |
|
Other non-current liabilities |
|
|
4,796 |
|
|
|
5,577 |
|
Total liabilities |
|
$ |
303,851 |
|
|
$ |
281,537 |
|
Shareholders’ equity: |
|
|
|
|
|
|
||
Common Stock: |
|
|
|
|
|
|
||
No par value; 55,000,000 shares authorized 33,132,691 and 33,008,185 issued and outstanding at June 30, 2022 and December 31, 2021, respectively |
|
|
121,088 |
|
|
|
118,646 |
|
Paid-in capital |
|
|
5,720 |
|
|
|
5,866 |
|
Accumulated other comprehensive loss |
|
|
(68,648 |
) |
|
|
(36,922 |
) |
Accumulated earnings |
|
|
585,035 |
|
|
|
566,216 |
|
Total shareholders’ equity |
|
|
643,195 |
|
|
|
653,806 |
|
Total liabilities and shareholders’ equity |
|
$ |
947,046 |
|
|
$ |
935,343 |
|
|
|
GENTHERM INCORPORATED
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
|
|
Six Months Ended June 30, |
|
|||||
|
|
2022 |
|
|
2021 |
|
||
Operating Activities: |
|
|
|
|
|
|
||
Net income |
|
$ |
18,819 |
|
|
$ |
57,700 |
|
Adjustments to reconcile net income to net cash (used in) provided by operating activities: |
|
|
|
|
|
|
||
Depreciation and amortization |
|
|
18,635 |
|
|
|
19,571 |
|
Deferred income taxes |
|
|
(997 |
) |
|
|
(225 |
) |
Non-cash stock based compensation |
|
|
5,263 |
|
|
|
7,663 |
|
Loss on disposition of property and equipment |
|
|
518 |
|
|
|
496 |
|
Other |
|
|
708 |
|
|
|
(262 |
) |
Changes in assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable, net |
|
|
(31,762 |
) |
|
|
11,647 |
|
Inventory |
|
|
(33,637 |
) |
|
|
(17,211 |
) |
Other assets |
|
|
(10,443 |
) |
|
|
8,408 |
|
Accounts payable |
|
|
27,768 |
|
|
|
(289 |
) |
Other liabilities |
|
|
1,442 |
|
|
|
(3,136 |
) |
Net cash (used in) provided by operating activities |
|
|
(3,686 |
) |
|
|
84,362 |
|
Investing Activities: |
|
|
|
|
|
|
||
Purchases of property and equipment |
|
|
(15,448 |
) |
|
|
(20,669 |
) |
Proceeds from the sale of property and equipment |
|
|
81 |
|
|
|
10 |
|
Cost of technology investments |
|
|
(350 |
) |
|
|
(5,200 |
) |
Net cash used in investing activities |
|
|
(15,717 |
) |
|
|
(25,859 |
) |
Financing Activities: |
|
|
|
|
|
|
||
Repayments of debt |
|
|
(1,250 |
) |
|
|
(143,731 |
) |
Proceeds from the exercise of Common Stock options |
|
|
569 |
|
|
|
6,292 |
|
Taxes withheld and paid on employees' share-based payment awards |
|
|
(4,464 |
) |
|
|
(2,117 |
) |
Acquisition contingent consideration payment |
|
|
— |
|
|
|
(69 |
) |
Net cash used in financing activities |
|
|
(5,145 |
) |
|
|
(139,625 |
) |
Foreign currency effect |
|
|
(8,800 |
) |
|
|
(360 |
) |
Net decrease in cash and cash equivalents |
|
|
(33,348 |
) |
|
|
(81,482 |
) |
Cash and cash equivalents at beginning of period |
|
|
190,606 |
|
|
|
268,345 |
|
Cash and cash equivalents at end of period |
|
$ |
157,258 |
|
|
$ |
186,863 |
|
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
||
Cash paid for taxes |
|
$ |
8,642 |
|
|
$ |
8,563 |
|
Cash paid for interest |
|
$ |
909 |
|
|
$ |
1,455 |
|
2022 Second Quarter Results Gentherm, Inc. August 2, 2022 Exhibit 99.2
Forward-Looking Statement Except for historical information contained herein, statements in this presentation are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent Gentherm Incorporated's goals, beliefs, plans and expectations about its prospects for the future and other future events. The forward-looking statements included in this presentation are made as of the date hereof or as of the date specified herein and are based on management's reasonable expectations and beliefs. Such statements are subject to a number of important assumptions, risks, uncertainties and other factors that may cause actual results or performance to differ materially from that described in or indicated by the forward-looking statements. Those risks include, but are not limited to, risks that: the COVID-19 pandemic and its direct and indirect adverse impacts on the automobile and medical industries and global economy, which had and are likely to continue to have, an adverse effect on, among other things, the Company’s results of operations, financial condition, cash flows, liquidity, business operations and stock price; the current supply-constrained environment we are facing involving component shortages, manufacturing disruptions, logistics challenges and inflationary pressures, and any future material delays or inflationary pressures in the supply chain of the Company or the automotive original equipment manufacturers (“OEMs”) or first tier suppliers (“Tier 1s”) supplied by the Company; the period of sustained price increases for various material components and shipping costs currently experienced in the automotive industry, which may continue for longer than we expect; risks relating to the Company’s recent acquisitions of Alfmeier and Dacheng (the “Acquisitions”), including: the Company’s increased debt leverage following the closing of the Acquisitions; risks inherent in the achievement of expected financial results, growth prospects and cost synergies for each of the Acquisitions and the timing thereof; and integration risks; the impact of industry or consumer behaviors on future automotive vehicle production and the Company’s strategy to develop and sell products tailored to evolving market demands, including the development and use of autonomous and electric vehicles and increasing use of car- and ride-sharing and on-demand transportation as a service, as well as related regulations; borrowing availability under the Company’s revolving credit facility; the Company’s failure to be in compliance with covenants under its debt agreements, which could result in the amounts outstanding thereunder being accelerated and becoming immediately due and payable; the Company’s ability to obtain additional financing by accessing the capital markets, which may not be available on acceptable terms or at all; the macroeconomic environment, including its impact on the automotive industry, which is cyclical; any significant declines in automobile production; market acceptance of the Company’s existing or new products, and new or improved competing products developed by competitors with greater resources; shifting customer preferences, including due to the evolving use of automobiles and technology; the Company’s ability to project future sales volumes, based on which the Company manages its business; reductions in new business awards due to the macroeconomic environment, COVID-19 and related uncertainties; the Company’s ability to convert new business awards into product revenues; the loss, material reduction in sales from or the insolvency of any of the Company’s key customers, including due to M&A or other market consolidation of OEMs and Tier 1s; the loss of any key suppliers; the impact of price downs in the ordinary course, or additional increased pricing pressures from the Company’s customers; the feasibility of Company’s development of new products on a timely, cost effective basis, or at all; security breaches and other disruptions to the Company’s IT systems; labor shortages, wage inflation and work stoppages impacting the Company, its suppliers or customers; changes in free trade agreements or the implementation of additional tariffs, and the Company’s ability to pass-through tariff costs; unfavorable changes to currency exchange rates and interest rates; the Company’s ability to protect its intellectual property in certain jurisdictions; the Company’s ability to effectively implement ongoing restructuring and other cost-savings measures or realize the full amount of estimated savings; compliance with, and increased costs related to, domestic and international regulations, including potential climate change regulations; the Ukraine-Russia conflict, which has led to and could lead to further challenges in our manufacturing operations in our Ukraine facility and further global economic sanctions and market disruptions, including significant volatility in commodity prices, credit and capital markets, supply constraints of natural gas, as well as supply chain interruptions; changes in government leadership and laws, political instability and economic tensions between governments; including as a result of the ongoing Ukraine Russian conflict and severe weather conditions and natural disasters and any resultant disruptions on the supply or production of goods or services or customer demands. The foregoing risks should be read in conjunction with the Company's filings with the Securities and Exchange Commission (the “SEC”), including “Risk Factors”, in its most recent Annual Report on Form 10-K and subsequent SEC filings, for a discussion of these and other risks and uncertainties. In addition, the business outlook discussed in this presentation does not include the potential impact of any business combinations, acquisitions, divestitures, strategic investments and other significant transactions that may be completed after the date hereof, each of which may present material risks to the Company’s future business and financial results. Except as required by law, the Company expressly disclaims any obligation or undertaking to update any forward-looking statements to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Use of Non-GAAP Financial Measures* In addition to the results reported herein in accordance with GAAP, the Company has provided here or elsewhere Adjusted Operating Expense, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, Free Cash Flow, Net Debt and Revenue excluding the impact of foreign currency translation, each a non-GAAP financial measure. See the Company’s earnings release dated August 2, 2022 for the definitions of each non-GAAP financial measure, information regarding why the Company utilizes such non-GAAP measures as supplemental measures of performance or liquidity, and their limitations. * See Appendix for certain reconciliations of GAAP to non-GAAP historical financial measures.
Automotive Highlights Outperformed Automotive production despite significant industry headwind Closed Alfmeier Acquisition 29 Vehicle launches with 15 OEMs in 2Q Multiple CCS® product launches Alfa Romeo Tonale BMW X5 Ford Ranger & Everest Mazda CX-50 Range Rover Sport Launched industry first proprietary Cell Connecting Board solution on the plug-in hybrid BMW 7 series The Fraunhofer Institute study estimates over 90 percent reduction in greenhouse gas emissions for the manufacture of the proprietary Cell Connecting Board solution Named Top North American Supplier by Honda for the third consecutive year
New Automotive Business Awards Strong debut as the largest global supplier of thermal and pneumatic comfort for Automotive $600M in awards in 2Q including Alfmeier Follow-on Production Vehicle Award for ClimateSenseTM Multiple CCS® awards Great Wall Honda Kia Nissan Stellantis Xpeng 17 Steering Wheel Heater awards across 12 OEMs Won high voltage cable award for a Porsche EV and Hydrogen Fuel Cell Electric Semi-Trucks Won pneumatic comfort award on BMW NCAR models Awarded a significant regional volume increase from one of the largest EV manufacturers for pneumatic comfort
Medical Highlights Expanding access to large and rapidly growing markets Completed the acquisition of Dacheng Medical Revenue up 9 percent year over year, excluding the impact of foreign currency translation Delivered Warm Air and Filtered Flo systems to United Nations Development Programme Won large Blanketrol award from Ascension Via Christi St. Francis Medical Center in Wichita, KS
Selected Income Statement Data 2022 2021 2022 2021 Product Revenues $260,715 $266,005 $528,372 $554,540 Automotive 249,152 255,105 507,016 534,475 Medical 11,563 10,900 21,356 20,065 Gross Margin 59,377 79,213 123,490 166,882 Gross Margin % 22.8% 29.8% 23.4% 30.1% Operating Expenses 51,642 47,541 101,565 94,461 Operating Income 7,735 31,672 21,925 72,421 Adjusted EBITDA 21,435 43,721 48,414 95,539 Adjusted EBITDA Margin 8.2% 16.4% 9.2% 17.2% Diluted EPS - As Adjusted $0.25 $0.85 $0.66 $1.89 Three Months Ended June 30, Six Months Ended June 30, (Dollars in thousands, except per share data)
Selected Balance Sheet Data June 30, 2022 December 31, 2021 Cash and Cash Equivalents $157,258 $190,606 Total Assets 947,046 935,343 Debt 37,500 38,750 Current 2,500 2,500 Non-Current 35,000 36,250 Revolving LOC Availability 357,017 440,000 Total Liquidity 514,275 630,606 (Dollars in thousands)
Product Revenue (1)(2)(4) $1.15B - $1.25B Adjusted EBITDA Margin(1)(3)(4) 10% - 12% Effective Tax Rate 29% - 31% Capital Expenditures(5) $50M - $60M Updates 2022 Guidance* * Includes the completed acquisition of Alfmeier as of August 1, 2022, and the completed acquisition of Dacheng Medical as of July 13, 2022. Based on the current forecast of customer orders, supply chain constraints, estimated recovery of industry-wide semiconductor supply, and light vehicle production in the Company’s key markets growing at a low single-digit rate in 2022 versus 2021. Foreign exchange rate assumed at current levels. Due to the inherent difficulty of forecasting the timing and amount of certain items that would impact net income margin, such as foreign currency gains and losses, we are unable to reasonably estimate net income margin, the GAAP financial measure most directly comparable to Adjusted EBITDA margin. Accordingly, we are unable to provide a reconciliation of Adjusted EBITDA margin to net income margin with respect to the guidance provided. Assumes approximately $100 million of product revenues and high single digit EBITDA margin rate from the acquisitions Includes the forecasted spending for Alfmeier
Appendix
Reconciliation of Adjusted EBITDA and Adjusted EBITDA Margin 2022 2021 2022 2021 Net Income $7,072 $24,791 $18,819 $57,700 Add Back: Depreciation and Amortization 8,998 9,628 18,485 19,323 Income Tax Expense 3,919 5,748 8,214 13,313 Interest Expense 1,430 630 1,999 1,669 Adjustments: Restructuring Expenses 374 2,091 555 2,882 Unrealized Currency Gain (4,024) (11) (6,340) (306) Acquisition Expenses 3,794 844 7,008 958 Other (128) — (326) — Adjusted EBITDA $21,435 $43,721 $48,414 $95,539 Product Revenues $260,715 $266,005 $528,372 $554,540 Net Income Margin 2.7% 9.3% 3.6% 10.4% Adjusted EBITDA Margin 8.2% 16.4% 9.2% 17.2% Three Months Ended June 30, Six Months Ended June 30,
Reconciliation of Adjusted EPS 2022 2021 2022 2021 Diluted EPS - As Reported $0.21 $0.74 $0.56 $1.72 Non-Cash Purchase Accounting Impact 0.05 0.06 0.11 0.12 Restructuring Expenses 0.01 0.06 0.02 0.09 Unrealized Currency Gain (0.12) — (0.19) (0.01) Acquisition Expenses 0.11 0.03 0.21 0.03 Other — — (0.01) — Tax Effect of Above (0.01) (0.04) (0.04) (0.06) Diluted EPS - As Adjusted $0.25 $0.85 $0.66 $1.89 Three Months Ended June 30, Six Months Ended June 30,
